About The Initiative

The Residual Risk Reduction Initiative (R3i) is a multidisciplinary, non-profit foundation established under Swiss law. Founded by international researchers and clinicians, R3i was created in response to the significant risk of both fatal and non-fatal macro- and micro-vascular complications in patients who are unaddressed by current standards of care.

The R3i is led by a Board of Trustees and an International Steering Committee (ISC) of 43 officers and members from the disciplines of cardiology, diabetology, lipidology, endocrinology, epidemiology, nutrition, ophthalmology, nephrology and basic science. The R3i Foundation was launched in November 2008, with Professor Jean-Charles Fruchart serving as its first President.

The objectives and programs of the R3i are defined in a manifesto published as a position paper in Diabetes and Vascular Disease Research (executive statement) and a supplement to The American Journal of Cardiology (full statement).1,2

The R3i is accredited by American Accreditation Commission International (AACI), one of the most experienced organizations in the provision of healthcare organization accreditation and clinical excellence certification services. AACI has awarded full medical content certification to the R3i from 2020 through to 2027

The mission of the Residual Risk Reduction Initiative (R3i) is to actively engage healthcare professionals in a global effort to combat the high incidence of macro-and micro-vascular complications in patients with residual vascular risk and unaddressed by current standards of care. By providing comprehensive education, and advocating for policy changes, we aim to significantly enhance the quality of life and longevity for millions affected by cardiovascular disease and diabetes.

The vision of the Residual Risk Reduction Initiative (R3i) is to substantially extend and improve the lives of patients with heart disease and/or diabetes who have atherogenic dyslipidemia and remain at significantly increased risk of vascular diseases including heart attacks, impaired kidney function, loss of sight and limb amputation despite receiving current standards of care.

What will the R3i achieve?

The initiative will have three major areas of activity:

to quantify the full extent of Residual Vascular Risk in patients with atherogenic dyslipidemia (cholesterol abnormalities increasing vascular risk) and to identify new targets for interventions.

– REALIST (REsiduAl risk, Lipids and Standard Therapies): 1st worldwide epidemiological survey to establish the link between TG/HDL-C and risk of CVD events (MACROvascular epidemiological survey) and microvascular complications of type 2 diabetes (MICROvascular epidemiological survey)

– Independent research grants related to Residual Vascular Risk

to create awareness of Residual Vascular Risk and encourage healthcare professionals, particularly Primary Care Physicians (PCPs), to translate the results of research into improved treatment strategies by providing global education programs:

– R3i website

– publications

– educational booklets editing

– access to slides kit library

– Webinars (live web conferences)

to ensure that the issue of Residual Vascular Risk associated with atherogenic dyslipidemia is given appropriate priority in international and national guidelines. Publications (position papers, literature reviews, etc) R3i scientific sessions at major international congresses R3i press events at major international congresses Collaboration with professional and patients’ groups, as well as policy makers.

Foundade by Professor Jean-Charles Fruchart in 2008, The Residual Risk Reduction Initiative (R3i) Foundation is a pioneering organization dedicated to addressing residual vascular risk through strategic initiatives. The R3i is a global, academic, multidisciplinary, non-profit Swiss foundation that brings together international researchers and clinicians who understand the significance of the elevated risk of fatal and non-fatal macro- and micro-vascular complications in patients already receiving current standard of care. Our foundation serves as a collaborative platform for healthcare professionals, researchers, and institutions committed to shaping future vascular strategies.

The R3i is led by a Board of Trustees and an International Steering Committee (ISC) of 43 officers and members from the disciplines of cardiology, diabetology, lipidology, endocrinology, epidemiology, nutrition, ophthalmology, nephrology and basic science.

The R3i is accredited by the American Accreditation Commission International (AACI), a highly experienced organization in healthcare organization accreditation and clinical excellence certification services. AACI has granted the R3i full medical content certification from 2020 to 2024.

• 1. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction initiative: A call to action to reduce Residual vascular Risk in dyslipidemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3i). Diabetes Vasc Dis Res 2008;5:319-35.
• 2. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction initiative: A call to action to reduce Residual vascular Risk in dyslipidemic patients. A full position paper by the Residual Risk Reduction Initiative (R3i). Am J Cardiol 2008:102:Supplement 10A.